---
document_datetime: 2025-12-02 05:27:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/raxone.html
document_name: raxone.html
version: success
processing_time: 0.1319143
conversion_datetime: 2025-12-28 15:02:59.989729
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Raxone

[RSS](/en/individual-human-medicine.xml/65947)

##### Authorised

This medicine is authorised for use in the European Union

idebenone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Raxone](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78699)
- [More information on Raxone](#more-information-on-raxone-79277)
- [More information on Raxone](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Raxone. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Raxone.

For practical information about using Raxone, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Raxone and what is it used for?

Raxone is a medicine used to treat visual impairment in adults and adolescents aged 12 years and over with Leber's hereditary optic neuropathy (LHON), an inherited disease characterised by progressive loss of sight. Raxone contains the active substance idebenone.

Because the number of patients with Leber's hereditary optic neuropathy is low, the disease is considered 'rare', and Raxone was designated an 'orphan medicine' (a medicine used in rare diseases) on 15 February 2007.

Raxone is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance, but Raxone contains idebenone at a different strength. The reference medicine for Raxone is Mnesis (45 mg tablets).

## How is Raxone used?

Raxone can only be obtained with a prescription and treatment should be started and supervised by a doctor with experience in LHON. Raxone is available as 150 mg tablets, and the recommended dose is two tablets taken three times a day with food.

## How does Raxone work?

The active substance in Raxone, idebenone, is an anti-oxidant agent that acts on mitochondria (the structures inside cells that produce the energy necessary for cells to function). Patients affected by LHON have mutations (defects) in the genetic material of mitochondria. This means that mitochondria do not work properly to generate energy, and produce toxic forms of oxygen (free radicals) that damage nerve cells in the eye that are needed for vision. Idebenone is thought to help improve production of energy by restoring mitochondrial function, thereby preventing the cellular damage and the loss of sight seen in LHON.

## What benefits of Raxone have been shown in studies?

Raxone has been investigated in one main study involving 85 patients with LHON, in which it was compared with placebo (a dummy treatment) over 24 weeks. The main measure of effectiveness was improvement in vision, mostly based on the numbers of letters patients were able to read on a standard eye test chart. By the end of the study, patients treated with Raxone were able to read on average 3 to 6 letters more compared with patients receiving placebo. Furthermore, some patients who were classified as 'off chart' (unable to read any letters on the chart) at the beginning of the study were able to read at least one line during the eye test after treatment, and this was also considered clinically important. Additionally, 30% of patients treated with Raxone (16 out of 53) had a clinically relevant recovery of vision in at least one eye, compared with 10% of patients (3 out of 29) in the placebo group.

Additional supportive data on the benefits of Raxone came from an expanded access program through which Raxone was made available to individual patients not participating in a clinical study, and from a case record survey, which included data from patients with LHON who did not receive any treatment.

Analyses of all these data showed a consistent pattern whereby generally a larger proportion of patients treated with Raxone had vision improvement compared with untreated or placebo-treated patients.

## What are the risks associated with Raxone?

The most common side effects with Raxone (which may affect more than 1 in 10 people) are nasopharyngitis and cough; mild to moderate diarrhoea and back pain are also common (affecting up to 1 in 10 people).

For the full list of all side effects and restrictions with Raxone, see the package leaflet.

## Why is Raxone approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Raxone are greater than its risks and recommended that it be approved for use in the EU.

The Committee noted the lack of treatments for preventing or reversing the vision loss in patients with LHON. The results of the main study showed an improvement in vision in patients treated with Raxone, and this trend towards a beneficial effect was confirmed by additional data from an expanded access program and a case record survey. With regard to the safety of Raxone, the majority of side effects seen with the medicine were mild or moderate in intensity.

Raxone has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about Raxone due to the rarity of the disease. Every year, the European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary.

## What information is still awaited for Raxone?

Since Raxone has been approved under exceptional circumstances, the company that markets Raxone will conduct additional studies on the long-term effects and safety of Raxone, and will establish and maintain a registry of LHON patients treated with Raxone.

## What measures are being taken to ensure the safe and effective use of Raxone?

A risk management plan has been developed to ensure that Raxone is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Raxone, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the .

## Other information about Raxone

The European Commission granted a marketing authorisation valid throughout the European Union for Raxone on 8 September 2015.

For more information about treatment with Raxone, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Raxone : EPAR - Summary for the public

Reference Number: EMA/452944/2015

English (EN) (77.03 KB - PDF)

**First published:** 17/09/2015

**Last updated:** 17/09/2015

[View](/en/documents/overview/raxone-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-82)

български (BG) (103.49 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/bg/documents/overview/raxone-epar-summary-public_bg.pdf)

español (ES) (75.48 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/es/documents/overview/raxone-epar-summary-public_es.pdf)

čeština (CS) (102.83 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/cs/documents/overview/raxone-epar-summary-public_cs.pdf)

dansk (DA) (74.48 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/da/documents/overview/raxone-epar-summary-public_da.pdf)

Deutsch (DE) (76.68 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/de/documents/overview/raxone-epar-summary-public_de.pdf)

eesti keel (ET) (74.22 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/et/documents/overview/raxone-epar-summary-public_et.pdf)

ελληνικά (EL) (105.3 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/el/documents/overview/raxone-epar-summary-public_el.pdf)

français (FR) (82.18 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/fr/documents/overview/raxone-epar-summary-public_fr.pdf)

hrvatski (HR) (98.92 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/hr/documents/overview/raxone-epar-summary-public_hr.pdf)

italiano (IT) (74.97 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/it/documents/overview/raxone-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.89 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/lv/documents/overview/raxone-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (99.82 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/lt/documents/overview/raxone-epar-summary-public_lt.pdf)

magyar (HU) (98.38 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/hu/documents/overview/raxone-epar-summary-public_hu.pdf)

Malti (MT) (103.13 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/mt/documents/overview/raxone-epar-summary-public_mt.pdf)

Nederlands (NL) (75.07 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/nl/documents/overview/raxone-epar-summary-public_nl.pdf)

polski (PL) (102.74 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/pl/documents/overview/raxone-epar-summary-public_pl.pdf)

português (PT) (75.56 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/pt/documents/overview/raxone-epar-summary-public_pt.pdf)

română (RO) (99.37 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/ro/documents/overview/raxone-epar-summary-public_ro.pdf)

slovenčina (SK) (102.54 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/sk/documents/overview/raxone-epar-summary-public_sk.pdf)

slovenščina (SL) (97.57 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/sl/documents/overview/raxone-epar-summary-public_sl.pdf)

Suomi (FI) (74.85 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/fi/documents/overview/raxone-epar-summary-public_fi.pdf)

svenska (SV) (75.13 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/sv/documents/overview/raxone-epar-summary-public_sv.pdf)

Raxone : EPAR - Risk-management-plan summary

English (EN) (113.75 KB - PDF)

**First published:** 17/09/2015

**Last updated:** 27/10/2022

[View](/en/documents/rmp-summary/raxone-epar-risk-management-plan-summary_en.pdf)

## Product information

Raxone : EPAR - Product Information

English (EN) (369.74 KB - PDF)

**First published:** 17/09/2015

**Last updated:** 20/08/2025

[View](/en/documents/product-information/raxone-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-146)

български (BG) (449.51 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/bg/documents/product-information/raxone-epar-product-information_bg.pdf)

español (ES) (389.46 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/es/documents/product-information/raxone-epar-product-information_es.pdf)

čeština (CS) (382.04 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/cs/documents/product-information/raxone-epar-product-information_cs.pdf)

dansk (DA) (393.09 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/da/documents/product-information/raxone-epar-product-information_da.pdf)

Deutsch (DE) (392.42 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/de/documents/product-information/raxone-epar-product-information_de.pdf)

eesti keel (ET) (378.71 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/et/documents/product-information/raxone-epar-product-information_et.pdf)

ελληνικά (EL) (457.12 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/el/documents/product-information/raxone-epar-product-information_el.pdf)

français (FR) (393.41 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/fr/documents/product-information/raxone-epar-product-information_fr.pdf)

hrvatski (HR) (451.53 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/hr/documents/product-information/raxone-epar-product-information_hr.pdf)

íslenska (IS) (401.66 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/is/documents/product-information/raxone-epar-product-information_is.pdf)

italiano (IT) (419.01 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/it/documents/product-information/raxone-epar-product-information_it.pdf)

latviešu valoda (LV) (428.25 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/lv/documents/product-information/raxone-epar-product-information_lv.pdf)

lietuvių kalba (LT) (425.32 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/lt/documents/product-information/raxone-epar-product-information_lt.pdf)

magyar (HU) (435.97 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/hu/documents/product-information/raxone-epar-product-information_hu.pdf)

Malti (MT) (439.05 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/mt/documents/product-information/raxone-epar-product-information_mt.pdf)

Nederlands (NL) (396.78 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/nl/documents/product-information/raxone-epar-product-information_nl.pdf)

norsk (NO) (382.4 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/no/documents/product-information/raxone-epar-product-information_no.pdf)

polski (PL) (441.14 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/pl/documents/product-information/raxone-epar-product-information_pl.pdf)

português (PT) (390.5 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/pt/documents/product-information/raxone-epar-product-information_pt.pdf)

română (RO) (437.64 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/ro/documents/product-information/raxone-epar-product-information_ro.pdf)

slovenčina (SK) (428.82 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/sk/documents/product-information/raxone-epar-product-information_sk.pdf)

slovenščina (SL) (429.06 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/sl/documents/product-information/raxone-epar-product-information_sl.pdf)

Suomi (FI) (382.07 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/fi/documents/product-information/raxone-epar-product-information_fi.pdf)

svenska (SV) (383.63 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

20/08/2025

[View](/sv/documents/product-information/raxone-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000291989 19/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Raxone : EPAR - All Authorised presentations

English (EN) (17.1 KB - PDF)

**First published:** 17/09/2015

**Last updated:** 17/09/2015

[View](/en/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-877)

български (BG) (43.45 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/bg/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.65 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/es/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_es.pdf)

čeština (CS) (31.9 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/cs/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.39 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/da/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.57 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/de/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (19.43 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/et/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (37.9 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/el/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_el.pdf)

français (FR) (17.4 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/fr/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (23.41 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/hr/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.03 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/is/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.43 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/it/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (32.77 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/lv/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.19 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/lt/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.29 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/hu/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.15 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/mt/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.41 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/nl/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.42 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/no/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_no.pdf)

polski (PL) (26.46 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/pl/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.55 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/pt/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.17 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/ro/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32.15 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/sk/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.82 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/sl/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.43 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/fi/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.4 KB - PDF)

**First published:**

17/09/2015

**Last updated:**

17/09/2015

[View](/sv/documents/all-authorised-presentations/raxone-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Raxone Active substance idebenone International non-proprietary name (INN) or common name idebenone Therapeutic area (MeSH) Optic Atrophy, Hereditary, Leber Anatomical therapeutic chemical (ATC) code N06BX13

### Pharmacotherapeutic group

- Psychoanaleptics
- Other psychostimulants and nootropics

### Therapeutic indication

Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON).

## Authorisation details

EMA product number EMEA/H/C/003834

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

Chiesi Farmaceutici S.p.A

Via Palermo 26/A

Opinion adopted 25/06/2015 Marketing authorisation issued 08/09/2015 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Raxone : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (184.12 KB - PDF)

**First published:** 20/08/2025

[View](/en/documents/procedural-steps-after/raxone-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Raxone : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (200.26 KB - PDF)

**First published:** 26/04/2018

**Last updated:** 21/08/2024

[View](/en/documents/procedural-steps-after/raxone-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

Questions and answers on the refusal of a change to the marketing authorisation for Raxone (idebenone)

Adopted

Reference Number: EMA/613204/2017

English (EN) (91.49 KB - PDF)

**First published:** 15/09/2017

**Last updated:** 26/01/2017

[View](/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-raxone-idebenone_en.pdf)

## Initial marketing authorisation documents

Raxone : EPAR - Public assessment report

Adopted

Reference Number: EMA/480039/2015

English (EN) (3.53 MB - PDF)

**First published:** 17/09/2015

**Last updated:** 17/09/2015

[View](/en/documents/assessment-report/raxone-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Raxone

Adopted

Reference Number: EMA/CHMP/368035/2015

English (EN) (70.31 KB - PDF)

**First published:** 26/06/2015

**Last updated:** 26/06/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-raxone_en.pdf)

#### News on Raxone

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2018) 26/01/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2017) 13/10/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2017) 15/09/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2015) 26/06/2015

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Raxone : EPAR - Product information - tracked changes

English (EN) (106.26 KB - DOCX)

**First published:** 20/08/2025

[View](/en/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-177)

български (BG) (109.99 KB - DOCX)

**First published:**

20/08/2025

[View](/bg/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_bg.docx)

español (ES) (105.77 KB - DOCX)

**First published:**

20/08/2025

[View](/es/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_es.docx)

čeština (CS) (106.53 KB - DOCX)

**First published:**

20/08/2025

[View](/cs/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (100.56 KB - DOCX)

**First published:**

20/08/2025

[View](/da/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (91.06 KB - DOCX)

**First published:**

20/08/2025

[View](/de/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (88.42 KB - DOCX)

**First published:**

20/08/2025

[View](/et/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (94.8 KB - DOCX)

**First published:**

20/08/2025

[View](/el/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_el.docx)

français (FR) (106.34 KB - DOCX)

**First published:**

20/08/2025

[View](/fr/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (105.36 KB - DOCX)

**First published:**

20/08/2025

[View](/hr/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (104.14 KB - DOCX)

**First published:**

20/08/2025

[View](/is/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_is.docx)

italiano (IT) (108.59 KB - DOCX)

**First published:**

20/08/2025

[View](/it/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (105.47 KB - DOCX)

**First published:**

20/08/2025

[View](/lv/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (91.95 KB - DOCX)

**First published:**

20/08/2025

[View](/lt/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (107.52 KB - DOCX)

**First published:**

20/08/2025

[View](/hu/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (87.3 KB - DOCX)

**First published:**

20/08/2025

[View](/mt/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (105.7 KB - DOCX)

**First published:**

20/08/2025

[View](/nl/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (98.78 KB - DOCX)

**First published:**

20/08/2025

[View](/no/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_no.docx)

polski (PL) (105.94 KB - DOCX)

**First published:**

20/08/2025

[View](/pl/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_pl.docx)

português (PT) (90.13 KB - DOCX)

**First published:**

20/08/2025

[View](/pt/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_pt.docx)

română (RO) (104.48 KB - DOCX)

**First published:**

20/08/2025

[View](/ro/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (104.28 KB - DOCX)

**First published:**

20/08/2025

[View](/sk/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (105.67 KB - DOCX)

**First published:**

20/08/2025

[View](/sl/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (103.53 KB - DOCX)

**First published:**

20/08/2025

[View](/fi/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (104.77 KB - DOCX)

**First published:**

20/08/2025

[View](/sv/documents/product-information-tracked-changes/raxone-epar-product-information-tracked-changes_sv.docx)

#### More information on Raxone

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-07-434) on 15 February 2007. Raxone was withdrawn from the Community register of orphan medicinal products in September 2025 at the end of the 10-year period of market exclusivity.

#### More information on Raxone

- [A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON) (PAROS) - post-authorisation study](https://catalogues.ema.europa.eu/study/48523)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/08/2025

## Share this page

[Back to top](#main-content)